AAP
JBIO

Arax Advisory Partners’s Jade Biosciences JBIO Stock Holding History

Arax Advisory Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46K Buy
104
+101
+3,367% +$1.46K ﹤0.01% 3196
2025
Q4 		$47 Sell
3
-152
-98% -$1.78K ﹤0.01% 3924
2025
Q3 		$1.34K Buy
155
+152
+5,067% +$1.24K ﹤0.01% 3195
2025
Q2 		$30 Hold
3
– – ﹤0.01% 3010
2025
Q1 		$294 Hold
3
– – ﹤0.01% 2579
2024
Q4 		$311 Hold
3
– – ﹤0.01% 2368
2024
Q3 		$245 Hold
3
– – ﹤0.01% 2496
2024
Q2 		$195 Buy
+3
New +$1.99K ﹤0.01% 2442

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Arax Advisory Partners's JBIO Position: Q1 2026 in Review

Arax Advisory Partners increased its Jade Biosciences (JBIO) stake by 3,367% in Q1 2026, buying an estimated $1.46K and bringing the position to 104 shares worth $1.46K. The position accounts for ﹤0.01% of the portfolio, ranked #3196.

Arax Advisory Partners first reported a position in JBIO in Q2 2024 and has held it in 8 quarters since. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Arax Advisory Partners held 104 shares of Jade Biosciences worth $1.46K as of Q1 2026.
  • Arax Advisory Partners bought 101 Jade Biosciences shares in Q1 2026, an estimated $1.46K.
  • Jade Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3196 holding.
  • Arax Advisory Partners first reported a position in Jade Biosciences in Q2 2024 and has held it in 8 quarters since.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.